Reviva Pharmaceuticals Bolsa (NASDAQ: RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa

REVIVA PHARMACEUTICALS HOLDI

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

B of A Securities analyst Robert Ohmes maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and raises the price target from $115 to $135.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Dollar General, Raises Price Target to $135

Introducing a simplified ride experience designed for older adults

UBER

Uber Launches Senior Accounts and Simple Mode

Barclays analyst Matthew Bouley maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and raises the price target from $190 to $247.

FERG

Barclays Maintains Overweight on Ferguson Enterprises, Raises Price Target to $247

WIIM

SGMT

Sagimet Biosciences shares are trading higher after the company announced its Phase 3 Denifanstat acne therapy clinical trial met all primary and secondary endpoints.

Baird analyst Joe Vruwink maintains ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Outperform and raises the price target from $106 to $124.

TTAN

Baird Maintains Outperform on ServiceTitan, Raises Price Target to $124

Barclays analyst Karen Short maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Overweight and raises the price target from $100 to $119.

Barclays Maintains Overweight on Dollar General, Raises Price Target to $119

ENSC

ENSC stock has given up its prior gain. Ensysce Biosciences shares were trading higher after the company announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse.

SXTP

60 Degrees Pharmaceuticals shares are trading higher after the company launched a new bottle format of ARAKODA.

Barclays analyst Theresa Chen maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underweight and raises the price target from $54 to $56.

Barclays Maintains Underweight on Cheniere Energy Partners, Raises Price Target to $56

Baird analyst David Koning maintains Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) with a Outperform and raises the price target from $36 to $40.

Baird Maintains Outperform on Paymentus Holdings, Raises Price Target to $40

Chart Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) and Flowserve Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) shares are trading higher premarket on Wednesday.
The companies reached an agreement to merge in an all-stock <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45766710/chart-industries-and-flowserve-corporation-to-combine-in-all-stock-merger-of-equals-creating-a-dif" rel="noreferrer noopener">transaction for $19 billion</a>.
As per the deal, Chart shareholders will receive 3.165 shares of Flowserve common stock for each Chart common stock share they own upon the transaction&#8217;s close.
The transaction is expected to close in the fourth quarter of 2025, subject to the approval of Chart and Flowserve shareholders, the receipt of regulatory approvals, and other closing conditions.
Post closure of the deal, Chart shareholders will own approximately 53.5% and Flowserve shareholders about 46.5% of the combined company on a fully diluted basis.
Synergies: The merger is projected to yield around $300 million in annual cost synergies within three<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> years of the transaction&#8217;s completion</a>.
Additionally, the combined companies expect to realize commercial revenue synergies over time, representing at least an incremental 2% growth on the new entity&#8217;s revenue.
The merger is anticipated to be meaningfully accretive to the combined company&#8217;s Adjusted EPS in the first year after closing.
Combined Company Details: As of the end of the first quarter of 2025, the combined entity generated approximately $8.8 billion in net revenue on a last twelve months (LTM) basis.
This revenue comes from diverse, high-growth, and attractive end markets, with roughly $3.7 billion (or about 42% of combined revenue) derived from aftermarket services.
With over 5.5 million assets installed across more than 50 countries, the merged company will manage the entire customer lifecycle, from initial process design to ongoing aftermarket support.
The new entity is projected to have a leverage ratio of 2.0x net debt to adjusted EBITDA at close.
Scott Rowe, president and CEO of Flowserve, said, &#8220;Chart&#8217;s and Flowserve&#8217;s highly complementary businesses will strengthen our ability to meet our customers&#8217; needs, empower innovation, and drive long-term, sustainable growth. The combined company will operate across diversified end markets with further exposure to premium, high-growth areas and a substantial aftermarket franchise – resulting in increased commercial opportunities.&#8221;
As of March 31, Flowserve&#8217;s cash and cash equivalents were <a href="https://www.benzinga.com/pressreleases/25/04/b45082726/flowserve-corporation-reports-first-quarter-2025-results" target="_blank" rel="noopener">$540.8 million,</a> and Chart Industries&#8217;<a href="https://www.benzinga.com/pressreleases/25/05/g45128922/chart-industries-reports-first-quarter-2025-financial-results" target="_blank" rel="noopener"> was $296.2</a><a href="https://www.benzinga.com/pressreleases/25/05/g45128922/chart-industries-reports-first-quarter-2025-financial-results" target="_blank" rel="noreferrer noopener"> million</a>.
Price Action: At the last check on Wednesday, GTLS shares were up 3.36% at $166.90, and FLS shares rose 5.38% at $53.25 premarket.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45568107" target="_blank" rel="noreferrer noopener">Solar Energy Stocks Drop As House Approves Major Rollback Of Climate Incentives</a></li>
</ul>
Photo: Shutterstock

GTLS

Chart Industries And Flowserve Announce $19 Billion Merger, Eyes $300 Million In Synergies

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">215.86</td>
<td align="right">0.42</td>
<td align="right">0.19</td>
<td>966</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">83.70</td>
<td align="right">0.12</td>
<td align="right">0.14</td>
<td>11.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">133.15</td>
<td align="right">0.12</td>
<td align="right">0.09</td>
<td>12.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.09</td>
<td align="right">0.01</td>
<td align="right">0.01</td>
<td>92.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.81</td>
<td align="right">0.01</td>
<td align="right">0.01</td>
<td>976</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.25</td>
<td align="right">-0.15</td>
<td align="right">-0.19</td>
<td>11.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">236.40</td>
<td align="right">-0.05</td>
<td align="right">-0.03</td>
<td>14.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">143.73</td>
<td align="right">-0.01</td>
<td align="right">-0.01</td>
<td>263</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">101.60</td>
<td align="right">-0.01</td>
<td align="right">-0.01</td>
<td>1.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 4, 2025

INAB

IN8bio shares are trading lower after the company announced a 1-for-30 reverse stock split.

Baird analyst Rob Oliver maintains Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) with a Outperform and raises the price target from $20 to $22.

BASE

Baird Maintains Outperform on Couchbase, Raises Price Target to $22

VCIG

VCI Global shares are trading higher. The company provided FY25 revenue guidance.

Bon Natural Life Limited shares are trading higher after the company announced a $1 million stock repurchase program.

Strategic move supports sharpened focus on family safety business
Smith Micro Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) today announced that it has sold its ViewSpot&#xAE; platform to a US-based company. The divestiture is another milestone in the Company's strategic plan to focus on its SafePath&#xAE; family safety solutions.
The transaction was completed on June 3, 2025.

SMSI

Smith Micro Software Sells ViewSpot Platform To US-Based Company; Terms Undisclosed

Baird analyst Rob Oliver maintains Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) with a Neutral and raises the price target from $13 to $15.

ASAN

Baird Maintains Neutral on Asana, Raises Price Target to $15

NCEW

New Century Logistics shares are trading higher after the company announced a proposal to acquire 51% of Asiatic Logistics.

Baird analyst Richard Eastman maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Outperform and raises the price target from $290 to $320.

ZBRA

Baird Maintains Outperform on Zebra Technologies, Raises Price Target to $320

Press Releases

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Health Care

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Earnings

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Comments

Reviva Pharmaceuticals

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL